Abstract
ObjectiveThis study aimed to evaluate the correlations between the triglyceride glucose-body mass index, the bedside index for severity in acute pancreatitis score, and the C-reactive protein-to-lymphocyte ratio with disease severity, as well as their prognostic value, in patients with hyperlipidemic acute pancreatitis.MethodsThis retrospective cohort study analyzed 247 patients diagnosed with hyperlipidemic acute pancreatitis. Participants were stratified according to the 2012 Atlanta criteria into mild (n = 108), moderately severe (n = 71), and severe (n = 68) groups. Based on 28-day outcomes, patients were categorized into poor prognosis (n = 90) and good prognosis (n = 157) groups. We compared baseline data and performed Spearman correlation analysis, Cox univariate/multivariate regression, and receiver operating characteristic analysis.ResultsThe triglyceride glucose-body mass index, bedside index for severity in acute pancreatitis, and C-reactive protein-to-lymphocyte ratio significantly increased with disease severity (p < 0.05) and demonstrated strong positive correlations (p < 0.01). Multivariate Cox regression identified triglyceride glucose-body mass index (hazard ratios = 1.62, 95% confidence intervals: 1.33-1.97), bedside index for severity in acute pancreatitis (hazard ratios = 1.92, 95% confidence intervals: 1.43-2.57), and C-reactive protein-to-lymphocyte ratio (hazard ratios = 2.05, 95% confidence intervals: 1.62-2.60) as independent predictors of poor prognosis. The combination of all three markers yielded the highest predictive accuracy (area under the curve = 0.987) for predicting 28-day poor prognosis, a finding that was robust on internal validation.ConclusionsThe triglyceride glucose-body mass index, bedside index for severity in acute pancreatitis score, and C-reactive protein-to-lymphocyte ratio are valuable tools for assessing disease severity and predicting prognosis in hyperlipidemic acute pancreatitis. Their combined use may potentially enhance early risk stratification and guide clinical decision-making.